Northern Trust Corp Has $14.83 Million Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Northern Trust Corp boosted its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 6.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 327,292 shares of the company's stock after purchasing an additional 20,743 shares during the quarter. Northern Trust Corp owned about 0.73% of Apogee Therapeutics worth $14,826,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Barclays PLC boosted its position in Apogee Therapeutics by 369.2% during the third quarter. Barclays PLC now owns 365,046 shares of the company's stock worth $21,443,000 after purchasing an additional 287,243 shares during the period. Swiss National Bank lifted its holdings in shares of Apogee Therapeutics by 17.5% during the fourth quarter. Swiss National Bank now owns 44,300 shares of the company's stock worth $2,007,000 after buying an additional 6,600 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Apogee Therapeutics by 22.2% during the fourth quarter. SG Americas Securities LLC now owns 9,890 shares of the company's stock worth $448,000 after buying an additional 1,796 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Apogee Therapeutics by 26.1% during the fourth quarter. JPMorgan Chase & Co. now owns 37,255 shares of the company's stock worth $1,688,000 after buying an additional 7,700 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Apogee Therapeutics during the fourth quarter worth approximately $226,000. Institutional investors own 79.04% of the company's stock.

Insider Activity

In other news, CEO Michael Thomas Henderson sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total transaction of $301,500.00. Following the sale, the chief executive officer now owns 1,292,987 shares in the company, valued at $38,983,558.05. This represents a 0.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Carl Dambkowski sold 1,590 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.48, for a total value of $48,463.20. Following the sale, the insider now owns 251,033 shares in the company, valued at approximately $7,651,485.84. This represents a 0.63% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,175 shares of company stock worth $587,191 in the last 90 days. Corporate insiders own 42.77% of the company's stock.

Wall Street Analyst Weigh In

APGE has been the subject of a number of recent research reports. Wedbush restated an "outperform" rating and issued a $90.00 target price on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Citigroup initiated coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $95.00 target price for the company. Finally, Guggenheim reiterated a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $94.60.

Apogee Therapeutics Stock Performance

APGE traded down $0.66 during midday trading on Wednesday, reaching $39.68. 16,144 shares of the company were exchanged, compared to its average volume of 522,655. Apogee Therapeutics, Inc. has a one year low of $26.20 and a one year high of $63.50. The stock has a market capitalization of $1.83 billion, a P/E ratio of -16.39 and a beta of 1.70. The stock's 50-day simple moving average is $36.72 and its 200 day simple moving average is $40.91.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.19) by $0.24. On average, research analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.